Ascendiant raised the firm’s price target on Lucid Diagnostics (LUCD) to $7.75 from $7.50 and keeps a Buy rating on the shares following the Q1 report. The firm says expected high growth in 2025 should drive the stock “much higher.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LUCD:
- Lucid Diagnostics Enters $25M Sales Agreement
- Lucid Diagnostics to join Russell 2000, Russell 3000 indexes
- Lucid Diagnostics director buys $457.6K in common stock
- Lucid Diagnostics files to sell 36.98M shares of common stock for holders
- Lucid Diagnostics Reports Increased Losses Amid Revenue Decline